Predict your next investment

Corporation
boryung.co.kr

See what CB Insights has to offer

Investments

1

Partners & Customers

5

About Boryung Pharmaceutical

Boryung Pharmaceutical (KRX: 003850) is a pharmaceutical company in South Korea fully integrated from R&D through manufacturing, marketing, and sales. The company has focused on the development and commercialization of new pharmaceutical products. Its main therapeutic categories are oncology, cardiovascular, anti-infective, and respiratory system.

Boryung Pharmaceutical Headquarter Location

136, Changgyeonggung-ro Jongno-gu

Seoul, 03127,

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Boryung Pharmaceutical News

Boryung opens CIS challenge to find healthcare solutions in space

Apr 20, 2022

Boryung opens CIS challenge to find healthcare solutions in space 바로가기 기자명 Kim Chan-hyuk 닫기 Boryung Pharmaceutical said it would open the first Care In Space (CIS) Challenge, a global competition event to find technologies and solutions for human health in space. Boryung leads the CIS challenge in collaboration with Axiom Space, an American human spaceflight services provider, and Starbust, a global aerospace startup accelerator. “As the era of space travel began recently, human activities are expected to get livelier in gravity-free space. Therefore, to preemptively respond to potential changes in human health in outer space, we have been preparing for the CIS project since 2020,” Boryung said. The CIS Challenge is part of the CIS project. Boryung said the challenge aimed to gather aerospace healthcare startups and those with creative ideas eager to find solutions to address various potential healthcare issues in space. Boryung will receive global participants’ applications and screen their ideas for the next three months. On July 28, a Pitch Day event will have selected applicants showcase their ideas at the UCLA Conference Hall. Then, on Demo Day in December, selected teams will have an opportunity to explain their ideas and solutions to investors worldwide. During the challenge period, experts from aerospace companies in the U.S. and Israel and major universities such as Stanford, Harvard, MIT, and Georgia Tech will verify ideas and provide tailored mentoring for business development. Details about the CIS challenge are available at cischallenge.com or Boryung’s website. Lim Dong-joo, head of the New Portfolio Investment Team at Boryung’s Global Investment Center, said the company would hold the CIS challenge annually to lead responses to healthcare issues in space. “We will discover new investment opportunities and establish ourselves as a must-have global partner in aerospace medicine,” he said.

Boryung Pharmaceutical Investments

1 Investments

Boryung Pharmaceutical has made 1 investments. Their latest investment was in ViGenCell as part of their Corporate Minority on July 7, 2016.

CBI Logo

Boryung Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/28/2016

Corporate Minority

ViGenCell

$1.33M

Yes

4

Date

7/28/2016

Round

Corporate Minority

Company

ViGenCell

Amount

$1.33M

New?

Yes

Co-Investors

Sources

4

Boryung Pharmaceutical Acquisitions

2 Acquisitions

Boryung Pharmaceutical acquired 2 companies. Their latest acquisition was Forbio Korea - Research Unit on February 08, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/8/2022

$99M

Acquired Unit

1

8/10/2017

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

2/8/2022

8/10/2017

Investment Stage

Series B

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$99M

Note

Acquired Unit

Subscribe to see more

Sources

1

10

Boryung Pharmaceutical Partners & Customers

5 Partners and customers

Boryung Pharmaceutical has 5 strategic partners and customers. Boryung Pharmaceutical recently partnered with Almirall on January 1, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

1/21/2022

Licensor

Spain

Boryung to market Almirall's spray-type hair loss treatment in Korea

Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve , a spray-type finasteride-based hair loss treatment , in Korea .

1

2/24/2021

Licensor

South Korea

Subscribe to see more

Subscribe to see more

10

1/1/2018

Licensor

Germany

Subscribe to see more

Subscribe to see more

10

9/27/2017

Licensor

United Kingdom

Subscribe to see more

Subscribe to see more

10

1/7/2013

Licensee

Russian Federation

Subscribe to see more

Subscribe to see more

10

Date

1/21/2022

2/24/2021

1/1/2018

9/27/2017

1/7/2013

Type

Licensor

Licensor

Licensor

Licensor

Licensee

Business Partner

Country

Spain

South Korea

Germany

United Kingdom

Russian Federation

News Snippet

Boryung to market Almirall's spray-type hair loss treatment in Korea

Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve , a spray-type finasteride-based hair loss treatment , in Korea .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.